195 related articles for article (PubMed ID: 15526817)
1. An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma.
Jönsson B; Berggren F; Svensson K; O'Byrne PM
Respir Med; 2004 Nov; 98(11):1146-54. PubMed ID: 15526817
[TBL] [Abstract][Full Text] [Related]
2. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study.
Lundborg M; Wille S; Bjermer L; Tilling B; Lundgren M; Telg G; Ekström T; Selroos O
Curr Med Res Opin; 2006 May; 22(5):809-21. PubMed ID: 16709303
[TBL] [Abstract][Full Text] [Related]
3. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study.
Price D; Haughney J; Lloyd A; Hutchinson J; Plumb J
Curr Med Res Opin; 2004 Oct; 20(10):1671-9. PubMed ID: 15462701
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy.
Price D; Wirén A; Kuna P
Allergy; 2007 Oct; 62(10):1189-98. PubMed ID: 17845590
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.
Wickstrøm J; Dam N; Malmberg I; Hansen BB; Lange P
Clin Respir J; 2009 Jul; 3(3):169-80. PubMed ID: 20298400
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
[TBL] [Abstract][Full Text] [Related]
9. Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study.
Andersson F; Stahl E; Barnes PJ; Löfdahl CG; O'Byrne PM; Pauwels RA; Postma DS; Tattersfield AE; Ullman A;
Respir Med; 2001 Jun; 95(6):505-12. PubMed ID: 11421509
[TBL] [Abstract][Full Text] [Related]
10. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
Pauwels RA; Löfdahl CG; Postma DS; Tattersfield AE; O'Byrne P; Barnes PJ; Ullman A
N Engl J Med; 1997 Nov; 337(20):1405-11. PubMed ID: 9358137
[TBL] [Abstract][Full Text] [Related]
11. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma.
Ställberg B; Ekström T; Neij F; Olsson P; Skoogh BE; Wennergren G; Löfdahl CG;
Respir Med; 2008 Oct; 102(10):1360-70. PubMed ID: 18723335
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma.
Ericsson K; Bantje TA; Huber RM; Borg S; Bateman ED
Respir Med; 2006 Apr; 100(4):586-94. PubMed ID: 16274980
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
Löfdahl CG; Ericsson A; Svensson K; Andreasson E
Pharmacoeconomics; 2005; 23(4):365-75. PubMed ID: 15853436
[TBL] [Abstract][Full Text] [Related]
14. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.
Miller E; FitzGerald JM
Can J Clin Pharmacol; 2008; 15(2):e165-76. PubMed ID: 18515918
[TBL] [Abstract][Full Text] [Related]
15. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma.
Sears MR; Boulet LP; Laviolette M; Fitzgerald JM; Bai TR; Kaplan A; Smiljanic-Georgijev N; Lee JS
Eur Respir J; 2008 May; 31(5):982-9. PubMed ID: 18216054
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland*.
Tamminen K; Laine J; Soini E; Martikainen J; Kankaanranta H
Curr Med Res Opin; 2008 Dec; 24(12):3453-61. PubMed ID: 19032127
[TBL] [Abstract][Full Text] [Related]
17. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma.
Brüggenjürgen B; Selim D; Kardos P; Richter K; Vogelmeier C; Roll S; Meyer-Sabellek W; Buhl R; Willich SN
Pharmacoeconomics; 2005; 23(7):723-31. PubMed ID: 15987228
[TBL] [Abstract][Full Text] [Related]
18. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
19. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.
Miller E; Sears MR; McIvor A; Liovas A
Can Respir J; 2007; 14(5):269-75. PubMed ID: 17703241
[TBL] [Abstract][Full Text] [Related]
20. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
